What Is PEMF Machine

Controversy over bone density testing in patients already taking osteoporosis medications.

The American Medical Association and other well-known medical organizations have determined that repeated bone density testing (DXA scans) is NOT indicated in routinely what is pemf machine monitoring the treatment or prevention of osteoporosis. It is scientifically earlier to measure bone density as a way to monitor the effectiveness of osteoporosis medications. Doctors do not know how to use these repeated bone density measurements during therapy. Some of the most important reasons are:

Bone density changes so slowly with treatment that the change is smaller than a machine measurement error. In other words, repeated DXA scans could not distinguish between an actual increase in bone density due to treatment or simply a variation of the measurement from the machine itself.

The real goal of osteoporosis treatment is to reduce future fractures. There was no good correlation between increased bone density with decreased risk of fracture with treatment. For example, alendronate has been shown to reduce the risk of fractures by 50%, but only to increase bone density by a few percent. In fact, much of the reduction in fractures with raloxifene is not explained by the effect of raloxifene on bone mineral density.

A density measurement taken during treatment will not help the doctor plan or change treatment. For example, although DXA scans show persistent bone density deterioration during treatment, there is no research data to suggest that changing medications, combining medications, or doubling medication doses will be safe and beneficial in reducing the risk of fractures in the future.

Important note: even if bone density declines during treatment, it is highly likely that patients will lose more bone density without treatment.

Recent research shows that women who lose bone density after the first year of menopausal hormone therapy will gain bone density in the next two years, whereas women who gain it in the first year will tend to lose density in the next two years of therapy. Therefore, bone density during treatment fluctuates naturally and this may not be related to drug fracture protection.

The U.S. Preventive Services Task Force and the American College of Physicians now recommend menopausal hormone therapy with estrogen or estrogen and progesterone

For all these reasons, surprising as it may sound to many people (and even some doctors), re-examining bone density is not at all like checking blood pressure during high blood buy pemf machine pressure treatment. Routine bone density testing during treatment may not be beneficial. However, in the future, if ongoing research brings in new technologies or new therapies, test results will change dramatically.